NR1H4 and metabolic dysfunction-associated steatotic liver disease: (Figure 1) FXR has been examined as a target for non-alcoholic fatty liver disease (NAFLD) by the efficacy of obeticholic acid (OCA) in clinical trials (Shen, et al., 2021).